A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib. Issue 9 (26th May 2020)

• Record Type: Journal Article
• Authors: Caldwell, Kenneth J.; De La Cuesta, Esther; Morin, Cara; Pappo, Alberto; Helmig, Sara
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 9(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-05-26
• Subjects: infantile fibrosarcoma -- larotrectinib -- NTRK -- pediatric; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28330
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Infantile fibrosarcoma (IFS) is a rare pediatric cancer that typically presents early in life. Surgical resection is commonly curative; however, resection is sometimes not possible requiring additional multimodal treatment. IFS commonly harbors a fusion in one of the neurotrophic receptor tyrosine kinase ( NTRK ) genes. Larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase (TRK), has been shown to be well tolerated and effective in children as young as 1‐month old. We report a case of IFS in a newborn treated with larotrectinib. The patient experienced a rapid clinical and radiographic response demonstrating the potential to treat newborns with larotrectinib.